Berlin's Health Overhaul Spurs Lilly Pullback and BioNTech's 1,860-Job Restructuring
04.06.2026 - 18:04:48 | boerse-global.de
The German government's proposed healthcare reforms are drawing fire from two heavyweight drugmakers, with Eli Lilly slashing its local investment by more than half and BioNTech accelerating a deep cost-cutting drive that will eliminate nearly a quarter of its workforce. The twin warnings underscore the fragile state of Germany's once-thriving pharma ecosystem.
Lilly said it would reduce planned spending at a German production site from $2.5 billion to roughly $1 billion, scrapping about 500 jobs in the process. The US group blamed the decision squarely on regulatory uncertainty, and BioNTech — itself a homegrown champion — has added its voice to the chorus of criticism. The Mainz-based company argues that the reforms risk long-term damage to Germany's appeal as a pharmaceutical hub.
BioNTech's own restructuring is already well underway. Four manufacturing sites — including those in Marburg and Tübingen — are slated for closure by the end of 2027, resulting in the loss of approximately 1,860 roles. The move is expected to generate annual savings of around €500 million by 2029, funds that management will plough into the oncology pipeline. The company now runs more than 25 phase 2 and phase 3 trials, 13 of which are considered pivotal.
The financial backdrop is strained. First-quarter revenue shrank to €118 million from €183 million a year earlier as Covid vaccine sales continued to fade, while the net loss ballooned to €532 million. BioNTech nevertheless sits on a cash pile of roughly €16.8 billion, which it is using to finance a share buyback of up to $1 billion — equivalent to about 4.2% of outstanding shares — that runs through May 2027.
Should investors sell immediately? Or is it worth buying BioNTech?
Investors have not been kind. The stock recently changed hands at €77.65, more than 20% below its level 12 months ago and well adrift of its 200-day moving average. A pair of down days following the presentation of Pumitamig data at the ASCO conference — the drug showed encouraging activity in lung cancer but failed to excite the market — drove the shares down 3.9% and then 3.2% in consecutive sessions. The relative strength index stands at 43.4, a neutral reading that offers no technical support for a rebound.
Analyst sentiment, however, remains far more optimistic than the share price suggests. Jefferies reiterated its buy rating with a $138 target on June 1. UBS upgraded the stock from Neutral to Buy shortly before, lifting its target to $135; research analyst David Dai highlighted what he sees as undervalued potential in the cancer pipeline. Bernstein's Jeffrey Walch struck a more cautious tone, initiating coverage at Market Perform with a $96 target. The consensus stands at "Moderate Buy" with a median price target of $129.56 — a chasm between Street conviction and market reality.
Adding to the uncertainty, founders U?ur ?ahin and Ă–zlem TĂĽreci are set to leave the company at year-end. The incoming management team inherits ambitious goals: ten cancer drug approvals by 2030. An application for BNT323, an antibody-based therapy, is expected later this year, and a series of late-stage readouts in the second half will test the pipeline's promise.
BioNTech at a turning point? This analysis reveals what investors need to know now.
For now, the combination of political headwinds, a shrinking workforce, and the huge gap between analyst expectations and investor sentiment leaves BioNTech in a precarious position. The next round of clinical data may shift the narrative, but the debate in Berlin over healthcare policy has added a layer of risk that no amount of oncology science can easily dispel.
Ad
BioNTech Stock: New Analysis - 4 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
